CS/BSE/NSE/PR/2016-2017

November 14, 2016

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,
Sub: Press Release

With reference to above subject, please find enclosed Press Release of our
company titled Suven Life Sciences presenting at Society for Neuroscience (SFN2016) San Diego
This is for your information and records
Thanking You,
Yours faithfully,
For Suven Life Sciences Limited
K. Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7
Banjara Hills I Hyderabad 500 034 I Telangana I India I C IN : L 24 1 10 TG 1 98 9 P L C 00 9 7 1 3
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

News Release
Suven Life Sciences presenting at Society for Neuroscience (SFN-2016)
San Diego.
HYDERABAD, INDIA (November 14th, 2016) Suven Life Sciences is participating and
presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from
their portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their
lead compound SUVN-502 at SFN 2016 being held at San Diego, USA during 12-16, 2016.
Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30
thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and
Clinical Research institutes will be participating at this conference
Key pharmacology, ADME, Safety and Phase-2 clinical trial status of SUVN-502 (5-HT6
receptor antagonist), Phase 1 clinical data of SUVN-G3031 (Histamine-3 receptor
antagonist) and SUVN-D4010 (5-HT4 receptor partial agonist) along with CB2 agonist and
Muscarinic (M1) acetylcholine receptor positive allosteric modulators (PAM) to treat the
unmet medical needs of patients living with cognitive dysfunction associated with
Alzheimers, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain
are being be presented by Suven scientists at SFN-2016. These data presentations
highlight Suvens continued commitment to explore new treatment options addressing
unmet medical need through novel mechanisms and targets and address a market size of
more than $35 billion.
Suven Life Science is a biopharmaceutical company focused on discovering, developing
and commercializing novel pharmaceutical products, which are first in class or best in class
CNS therapies through the use of GPCR targets. Suven has 4 clinical stage compounds, a
Phase 2 undergoing SUVN-502, Phase 1 completed SUVN-G3031 and SUVN-D4010 for
Alzheimers disease and Schizophrenia along with Phase 1 ready SUVN-911 for Major
Depressive Disorder (MDD). In addition to that the Company has nine (9) internallydiscovered therapeutic drug candidates currently in pre-clinical stage of development
targeting conditions such as ADHD, dementia, depression, Huntingtons disease,
Parkinsons disease and pain.
For more information please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including
expectations and assumptions, contained in this news release may be forward-looking statements that
involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these
forward-looking statements, it is possible that future circumstances might differ from the assumptions on
which such statements are based. Other important factors which could cause results to differ materially
including outsourcing trends, economic conditions, dependence on collaborative partnership programs,
retention of key personnel, technological advances and continued success in growth of sales that may make
our products/services offerings less competitive; Suven may not undertake to update any forward-looking
statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th FloorRoad No.5 I Avenue 7
Banjara Hills I Hyderabad 500 034 I Telangana I India I C IN : L 24 1 10 TG 1 98 9 P L C 00 9 7 1 3
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com